File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo

TitleGold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo
Authors
KeywordsChemotherapeutics
Cisplatin
Gold(III)
Nasopharyngeal carcinoma
Neoplasm
Porphyrin
Issue Date2009
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
Citation
International Journal Of Cancer, 2009, v. 124 n. 8, p. 1971-1979 How to Cite?
AbstractNasopharyngeal carcinoma (NPC) is a common neoplasm in Southeastern Asia, and cisplatin-containing regimens for combinational chemotherapy are widely used for treating locally recurrent or metastatic diseases. However, resistance to cisplatin is not infrequently seen and its associated side effects may be life-threatening. In this report, another metallo-pharmaceutical agent gold(III) porphyrin complex [Au(TPP)]Cl was investigated in comparison to cisplatin for its in vitro and in vivo anticancer effects. Through induction of the intrinsic apoptosis pathway, [Au(TPP)]Cl exhibited 100-fold higher potency than cisplatin in killing NPC cells, including cisplatin-sensitive and cisplatin-resistant variants, and also an variant harboring the Epstein-Barr virus. In addition, a safety concentration window was demonstrated, allowing [Au(TPP)]Cl to kill tumors with minimal cytotoxicity to noncancerous cells. More importantly, weekly intraperitoneal injection of 3 mg/kg [Au(TPP)]Cl was more effective than the same dose of cisplatin in inducing tumor apoptosis in vivo and remarkably inhibited tumor growth in animals without any noticeable side effect. [Au(TPP)]Cl therefore is a promising chemotherapeutic agent that deserves further development as a novel drug for the treatment of advanced NPC, in particular, for cases with cisplatin-resistance. © 2008 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/132490
ISSN
2014 Impact Factor: 5.085
2014 SCImago Journal Rankings: 2.175
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuk, FTen_HK
dc.contributor.authorSun, RWYen_HK
dc.contributor.authorChen, Yen_HK
dc.contributor.authorChan, VSFen_HK
dc.contributor.authorYu, WYen_HK
dc.contributor.authorTam, PKHen_HK
dc.contributor.authorChe, CMen_HK
dc.contributor.authorLin, CLSen_HK
dc.date.accessioned2011-03-28T09:25:20Z-
dc.date.available2011-03-28T09:25:20Z-
dc.date.issued2009en_HK
dc.identifier.citationInternational Journal Of Cancer, 2009, v. 124 n. 8, p. 1971-1979en_HK
dc.identifier.issn0020-7136en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132490-
dc.description.abstractNasopharyngeal carcinoma (NPC) is a common neoplasm in Southeastern Asia, and cisplatin-containing regimens for combinational chemotherapy are widely used for treating locally recurrent or metastatic diseases. However, resistance to cisplatin is not infrequently seen and its associated side effects may be life-threatening. In this report, another metallo-pharmaceutical agent gold(III) porphyrin complex [Au(TPP)]Cl was investigated in comparison to cisplatin for its in vitro and in vivo anticancer effects. Through induction of the intrinsic apoptosis pathway, [Au(TPP)]Cl exhibited 100-fold higher potency than cisplatin in killing NPC cells, including cisplatin-sensitive and cisplatin-resistant variants, and also an variant harboring the Epstein-Barr virus. In addition, a safety concentration window was demonstrated, allowing [Au(TPP)]Cl to kill tumors with minimal cytotoxicity to noncancerous cells. More importantly, weekly intraperitoneal injection of 3 mg/kg [Au(TPP)]Cl was more effective than the same dose of cisplatin in inducing tumor apoptosis in vivo and remarkably inhibited tumor growth in animals without any noticeable side effect. [Au(TPP)]Cl therefore is a promising chemotherapeutic agent that deserves further development as a novel drug for the treatment of advanced NPC, in particular, for cases with cisplatin-resistance. © 2008 Wiley-Liss, Inc.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/homeen_HK
dc.relation.ispartofInternational Journal of Canceren_HK
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectChemotherapeutics-
dc.subjectCisplatin-
dc.subjectGold(III)-
dc.subjectNasopharyngeal carcinoma-
dc.subjectNeoplasm-
dc.subjectPorphyrin-
dc.subject.meshAnimalsen_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic useen_HK
dc.subject.meshCarcinoma - drug therapyen_HK
dc.subject.meshCell Differentiationen_HK
dc.subject.meshCell Line, Tumoren_HK
dc.subject.meshCisplatin - therapeutic useen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGold - administration & dosageen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMice, Inbred BALB Cen_HK
dc.subject.meshModels, Chemicalen_HK
dc.subject.meshNasopharyngeal Neoplasms - drug therapyen_HK
dc.subject.meshPorphyrins - administration & dosageen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleGold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivoen_HK
dc.typeArticleen_HK
dc.identifier.emailSun, RWY:rwysun@hku.hken_HK
dc.identifier.emailChan, VSF:sfvchan@hku.hken_HK
dc.identifier.emailTam, PKH:paultam@hkucc.hku.hken_HK
dc.identifier.emailChe, CM:cmche@hku.hken_HK
dc.identifier.authoritySun, RWY=rp00781en_HK
dc.identifier.authorityChan, VSF=rp01459en_HK
dc.identifier.authorityTam, PKH=rp00060en_HK
dc.identifier.authorityChe, CM=rp00670en_HK
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1002/ijc.24130en_HK
dc.identifier.pmid19107930en_HK
dc.identifier.scopuseid_2-s2.0-62449242847en_HK
dc.identifier.hkuros155198-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-62449242847&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume124en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1971en_HK
dc.identifier.epage1979en_HK
dc.identifier.eissn1097-0215-
dc.identifier.isiWOS:000264452700028-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYuk, FT=8617703300en_HK
dc.identifier.scopusauthoridSun, RWY=26325835800en_HK
dc.identifier.scopusauthoridChen, Y=16416830300en_HK
dc.identifier.scopusauthoridChan, VSF=35200370000en_HK
dc.identifier.scopusauthoridYu, WY=7403913673en_HK
dc.identifier.scopusauthoridTam, PKH=7202539421en_HK
dc.identifier.scopusauthoridChe, CM=7102442791en_HK
dc.identifier.scopusauthoridLin, CLS=37099293900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats